Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VRCA 
Verrica Pharmaceuticals Inc (VRCA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: VRCA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15
1 Year Target Price $15
| 2 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -23.25% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 39.20M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 5 | Beta 1.71 | 52 Weeks Range 3.82 - 17.38 | Updated Date 10/17/2025 |
52 Weeks Range 3.82 - 17.38 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.74 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) 11.89% |
Management Effectiveness
Return on Assets (TTM) -51.93% | Return on Equity (TTM) -1546.58% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 66379786 | Price to Sales(TTM) 2.67 |
Enterprise Value 66379786 | Price to Sales(TTM) 2.67 | ||
Enterprise Value to Revenue 4.51 | Enterprise Value to EBITDA -11.7 | Shares Outstanding 9445768 | Shares Floating 1935532 |
Shares Outstanding 9445768 | Shares Floating 1935532 | ||
Percent Insiders 43.45 | Percent Institutions 26.38 |
Upturn AI SWOT
Verrica Pharmaceuticals Inc
Company Overview
History and Background
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing and commercializing novel treatments for viral skin diseases requiring medical intervention. Founded in 2013, the company has focused on addressing unmet needs in dermatology.
Core Business Areas
- Dermatology Therapeutics: Focuses on developing and commercializing treatments for viral skin diseases, primarily molluscum contagiosum. Their main product is YCANTH, a drug for this condition.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives with expertise in drug development and commercialization. The organizational structure is typical for a biotechnology company, with departments dedicated to research, development, commercial operations, and administration.
Top Products and Market Share
Key Offerings
- YCANTH (cantharidin): YCANTH is Verrica's FDA-approved drug for the treatment of molluscum contagiosum. Competitors include off-label treatments and other experimental therapies. While precise market share data is limited, YCANTH aims to capture a significant portion of the molluscum contagiosum treatment market. Revenue data is dependent on sales since its approval. Other treatment alternatives include curettage, cryotherapy, and topical medications.
Market Dynamics
Industry Overview
The dermatology therapeutics market is characterized by increasing demand for effective treatments for various skin conditions. There is also an increase in dermatological conditions in the pediatric and adolescent population, such as molluscum contagiosum. The demand for treatment is further driven by public awareness and medical advancement
Positioning
Verrica is positioned as a leader in the molluscum contagiosum treatment space with YCANTH, which offers a professionally applied treatment option. Its competitive advantage lies in its FDA-approved product and focused approach.
Total Addressable Market (TAM)
The estimated TAM for molluscum contagiosum treatments is approximately $500 million to $1 billion annually. Verrica is positioned to capture a significant portion of this market with YCANTH.
Upturn SWOT Analysis
Strengths
- FDA-approved product (YCANTH)
- Focus on a specific unmet medical need (molluscum contagiosum)
- Experienced leadership team
Weaknesses
- Single product dependency
- Commercialization risks (launch execution)
- Reliance on professional administration of the drug
Opportunities
- Expansion of YCANTH to other markets
- Development of new formulations or indications
- Strategic partnerships with other pharmaceutical companies
Threats
- Competition from off-label treatments
- Pricing and reimbursement pressures
- Clinical trial failures for pipeline products
Competitors and Market Share
Key Competitors
- None, YCANTH is the only FDA-approved drug for molluscum contagiosum. Other approaches include off label medication
Competitive Landscape
Verrica has a distinct advantage by having the only FDA-approved drug for molluscum contagiosum. However, off label treatments can be prescribed.
Growth Trajectory and Initiatives
Historical Growth: Verrica's historical growth has been dependent on clinical development progress and regulatory approvals. (Data not included).
Future Projections: Future growth depends on the successful commercialization of YCANTH and the advancement of its pipeline. Analyst estimates are needed for further information. (Data not included).
Recent Initiatives: Recent initiatives include commercial launch of YCANTH and ongoing clinical trials for other indications.
Summary
Verrica Pharmaceuticals is a dermatology company with its only product being YCANTH, the only FDA approved drug for treating molluscum contagiosum. Its biggest strength is the limited competion for its main product. Their commercial success will depend on the execution of their commercial strategy. They have no diversity in products so they need to be aware of this and add more product lines.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Press releases
- Analyst reports (where available)
- FDA website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance can change rapidly. Consult with a financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Verrica Pharmaceuticals Inc
Exchange NASDAQ | Headquaters West Chester, PA, United States | ||
IPO Launch date 2018-06-15 | President, CEO & Director Dr. Jayson M. Rieger M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 71 | Website https://www.verrica.com |
Full time employees 71 | Website https://www.verrica.com | ||
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company's product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.